Reversal of liver cirrhosis: Current evidence and expectations

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.

Original languageEnglish
Pages (from-to)213-228
Number of pages16
JournalKorean Journal of Internal Medicine
Volume32
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Liver Cirrhosis
Hepatic Stellate Cells
Fibrosis
Liver
Blood Vessels
Liver Diseases
Collagen
Therapeutics
Clinical Trials
Biopsy

Keywords

  • Fibrosis
  • Hepatic stellate cells
  • Liver cirrhosis
  • Reversal
  • Therapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Reversal of liver cirrhosis : Current evidence and expectations. / Jung, Young Kul; Yim, Hyung Joon.

In: Korean Journal of Internal Medicine, Vol. 32, No. 2, 01.01.2017, p. 213-228.

Research output: Contribution to journalReview article

@article{32898bf1f1f643928eec4fc02f6646cd,
title = "Reversal of liver cirrhosis: Current evidence and expectations",
abstract = "In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.",
keywords = "Fibrosis, Hepatic stellate cells, Liver cirrhosis, Reversal, Therapy",
author = "Jung, {Young Kul} and Yim, {Hyung Joon}",
year = "2017",
month = "1",
day = "1",
doi = "10.3904/kjim.2016.268",
language = "English",
volume = "32",
pages = "213--228",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

TY - JOUR

T1 - Reversal of liver cirrhosis

T2 - Current evidence and expectations

AU - Jung, Young Kul

AU - Yim, Hyung Joon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.

AB - In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.

KW - Fibrosis

KW - Hepatic stellate cells

KW - Liver cirrhosis

KW - Reversal

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85014810355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014810355&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.268

DO - 10.3904/kjim.2016.268

M3 - Review article

C2 - 28171717

AN - SCOPUS:85014810355

VL - 32

SP - 213

EP - 228

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 2

ER -